Negredo Eugenia, Puig Jordi, Aldea David, Medina Manuel, Estany Carla, Pérez-Alvarez Núria, Rodríguez-Fumaz Carmina, Muñoz-Moreno Jose A, Higueras Carmen, Gonzalez-Mestre Vicente, Clotet Bonaventura
Lluita contra la SIDA Foundation, Germans Trias i Pujol University Hospital, Universitat Autònoma de Barcelona, Barcelona, Spain.
AIDS Res Hum Retroviruses. 2009 Apr;25(4):451-5. doi: 10.1089/aid.2008.0230.
Infiltrations with synthetic substances are effective strategies for repairing facial lipoatrophy. However, few data are available on long-term safety. We describe the safety of polyacrylamide hydrogel in 145 patients who received facial infiltrations with Aquamid from September 2002 to April 2004. Epidemiological, clinical (mainly complications), and psychological data (patient satisfaction) were collected. We also recorded all patients who presented with a local infection at any time after receiving an infiltration. Sixty-two percent of patients presented with severe facial lipoatrophy before infiltration. The cumulative volume of Aquamid injected was 5.5 ml (4-18) per patient. During a mean (SD) of 50.2 (4.3) months after infiltration, only one patient presented with a local infection. Small palpable, nonvisible nodules or indurations were the most frequent complications (19.3% and 6.2%, respectively). If we include the remaining patients from our center (n = 294) who also received Aquamid (although less than 4 years ago), a further three patients presented with a local infection (incidence of 0.9%). Most patients (88.9%) were "satisfied" or "very satisfied" with the results; patients with mild to moderate baseline facial lipoatrophy were more satisfied than those with severe lipoatrophy ("very satisfied": 92.7% versus 86.5%, respectively). Only 17.4% reported mild impairment of lipoatrophy and only 9.2% required new infiltrations; however, 76% would have preferred more infiltrations. The high patient satisfaction and the low number of severe complications after at least 4 years of facial infiltrations with Aquamid reflect the long-term safety of this product for the repair of facial lipoatrophy. However, prolonged follow-up of these patients is recommended to detect unexpected long-term adverse reactions.
使用合成物质进行填充是修复面部脂肪萎缩的有效策略。然而，关于长期安全性的数据却很少。我们描述了2002年9月至2004年4月期间145例接受Aquamid面部填充患者的聚丙烯酰胺水凝胶安全性。收集了流行病学、临床（主要是并发症）和心理数据（患者满意度）。我们还记录了所有在接受填充后任何时间出现局部感染的患者。62%的患者在填充前存在严重面部脂肪萎缩。每位患者注射的Aquamid累积体积为5.5毫升（4 - 18毫升）。在填充后的平均（标准差）50.2（4.3）个月期间，只有1例患者出现局部感染。可触及但不可见的小结节或硬结是最常见的并发症（分别为19.3%和6.2%）。如果纳入我们中心另外294例也接受了Aquamid填充的患者（尽管时间不到4年），又有3例患者出现局部感染（发生率为0.9%）。大多数患者（88.9%）对结果“满意”或“非常满意”；基线面部脂肪萎缩为轻度至中度的患者比严重脂肪萎缩患者更满意（“非常满意”：分别为92.7%和86.5%）。只有17.4%的患者报告脂肪萎缩有轻度改善，只有9.2%的患者需要再次填充；然而，76%的患者希望能有更多填充。用Aquamid进行面部填充至少4年后患者满意度高且严重并发症数量少，这反映了该产品用于修复面部脂肪萎缩的长期安全性。然而，建议对这些患者进行长期随访，以发现意外的长期不良反应。
